menu
Taltz Icon Taltz Icon

Taltz—a targeted interleukin-17A (IL-17A) antagonist for
adults with moderate to severe plaque psoriasis

STARTYOUR PATIENTSTODAY

Receive the latest updates about taltz

You are registering to receive information about Taltz (intended for healthcare providers only). By submitting the information requested below, you certify that you are a healthcare provider. Lilly's intent is to provide information only to healthcare providers.

Personal information

Important:

The information you provide in this form will be used in accordance with the Lilly Privacy Statement. The information you provide to Lilly and its alliance partners may also be used for marketing purposes. Also, any information or suggestions you provide regarding the content of any Lilly website, published document, or product will be handled in accordance with our Copyright Policy.

By submitting this registration form, I agree that my use of this website and any emails I receive in response to this registration are subject to this website’s Terms of Use, Privacy Statement, and Copyright Policy. I have read the Terms of Use, Privacy Statement, and Copyright Policy contained on this website and agree to be bound by such terms.

Indication and Important Safety Information

Taltz is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

important safety information

Contraindications

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Warnings and Precautions

Infections

Taltz may increase the risk of infection. The Taltz group had a higher rate of infections than the placebo group (27% vs 23%). Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment.

Hypersensitivity

Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease.

Immunizations

Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Live vaccines should not be given with Taltz.

Adverse Reactions

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Please see full Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 22MAR2016